Figure 4.
APA signatures are potent biomarkers (example shown for neuroblastomas). (A) High level PCF11 associates with lower survival probability. (B) PCF11-directed APA changes (APA ratio) represent potent prognostic biomakers (a current commonly used biomarker is shown in blue). In contrast, mere mRNA abundance changes of APA-affected targets (e.g., PVRL1, GNP2 or IGF1R) do not possess diagnostic potential (C). Thus, even genes with previously identified insignificant RNA abundance changes may possess strong diagnostic potential when qualitative aspects (APA ratio reflecting different transcript isoforms) are considered.
